Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGγ

Cancer Letters

Volumn 360, Issue 2, 2015, Pages 269-279

  Wang, Huihui ^a   Bao, Wei ^a   Jiang, Feizhou ^a   Che, Qi ^a   Chen, Zheng ^a   Wang, Fangyuan ^a   Tong, Huan ^a   Dai, Chenyun ^a   He, Xiaoying ^a   Liao, Yun ^b   Liu, Binya ^b   Sun, Jing ^b   Wan, Xiaoping ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

EC; EMT; Invasion; Mutant p53; Proliferation; REG

Indexed keywords

NERVE CELL ADHESION MOLECULE; PEPTIDES AND PROTEINS; REG GAMMA PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; AUTOANTIGEN; KI ANTIGEN; PARAFFIN; PROTEASOME; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; P53 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REG GAMMA GENE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; ENZYMOLOGY; GENETICS; MUTATION; NUDE MOUSE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ANIMALS; AUTOANTIGENS; CARCINOMA, ENDOMETRIOID; CELL GROWTH PROCESSES; CELL MOVEMENT; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENES, P53; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; PARAFFIN EMBEDDING; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84924907816     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.028     Document Type: Article

References (58)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin 2015, 65:5-29.
2. Rose P.G. Endometrial carcinoma. N. Engl. J. Med 1996, 335:640-649.
3. Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann. Oncol 2007, 18:409-420.
4. Johnson N., Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007, 114:1313-1320.
5. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000, 60:6788-6793.
6. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., et al. Gain of function mutations in p53. Nat. Genet 1993, 4:42-46.
7. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
8. Lax S.F., Kendall B., Tashiro H., Slebos R.J., Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
9. Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H., Jones M.W. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod. Pathol 2000, 13:379-388.
10. Shih H.C., Shiozawa T., Kato K., Imai T., Miyamoto T., Uchikawa J., et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum. Pathol 2003, 34:471-478.
11. Dedes K.J., Wetterskog D., Ashworth A., Kaye S.B., Reis-Filho J.S. Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol 2011, 8:261-271.
12. Mariani A., Sebo T.J., Webb M.J., Riehle D., Katzmann J.A., Keeney G.L., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect. Prev 2003, 27:434-441.
13. Norimatsu Y., Ohsaki H., Yanoh K., Kawanishi N., Kobayashi T.K. Expression of immunoreactivity of nuclear findings by p53 and cyclin a in endometrial cytology: comparison with endometrial glandular and stromal breakdown and endometrioid adenocarcinoma grade 1. Diagn. Cytopathol 2013, 41:303-307.
14. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev 2012, 26:1268-1286.
15. Hanel W., Marchenko N., Xu S., Yu S.X., Weng W., Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013, 20:898-909.
16. Xu J., Wang J., Hu Y., Qian J., Xu B., Chen H., et al. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis 2014, 5:e1108.
17. Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet 2006, 95(Suppl. 1):S105-S143.
18. Ashworth A., Lord C.J., Reis-Filho J.S. Genetic interactions in cancer progression and treatment. Cell 2011, 145:30-38.
19. Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z. The proteasome as a target for cancer therapy. Clin. Cancer Res 2003, 9:6316-6325.
20. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol 2005, 23:630-639.
21. Ma C.P., Slaughter C.A., DeMartino G.N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem 1992, 267:10515-10523.
22. Dubiel W., Pratt G., Ferrell K., Rechsteiner M. Purification of an 11 S regulator of the multicatalytic protease. J. Biol. Chem 1992, 267:22369-22377.
23. Li X., Lonard D.M., Jung S.Y., Malovannaya A., Feng Q., Qin J., et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 2006, 124:381-392.
24. Chen X., Barton L.F., Chi Y., Clurman B.E., Roberts J.M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 2007, 26:843-852.
25. Li X., Amazit L., Long W., Lonard D.M., Monaco J.J., O'Malley B.W. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 2007, 26:831-842.
26. Okamura T., Taniguchi S., Ohkura T., Yoshida A., Shimizu H., Sakai M., et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J. Clin. Endocrinol. Metab 2003, 88:1374-1383.
27. Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M.L., Palme S., Berndt P., et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 2006, 5:2092-2101.
28. Wang X., Tu S., Tan J., Tian T., Ran L., Rodier J.F., et al. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med. Oncol 2011, 28:31-41.
29. Li L.P., Cheng W.B., Li H., Li W., Yang H., Wen D.H., et al. Expression of proteasome activator REGgamma in human laryngeal carcinoma and associations with tumor suppressor proteins. Asian Pac. J. Cancer Prev 2012, 13:2699-2703.
30. He J., Cui L., Zeng Y., Wang G., Zhou P., Yang Y., et al. REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer 2012, 12:75.
31. Llobet D., Eritja N., Encinas M., Sorolla A., Yeramian A., Schoenenberger J.A., et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008, 19:115-124.
32. Ali A., Wang Z., Fu J., Ji L., Liu J., Li L., et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat. Commun 2013, 4:2667.
33. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int. J. Gynaecol. Obstet 2009, 105:109.
34. Bao W., Wang H.H., Tian F.J., He X.Y., Qiu M.T., Wang J.Y., et al. A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol. Cancer 2013, 12:155.
35. Li B.L., Lu C., Lu W., Yang T.T., Qu J., Hong X., et al. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med. Oncol 2013, 30:484.
36. Yaginuma Y., Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 1991, 51:6506-6509.
37. Ramondetta L., Mills G.B., Burke T.W., Wolf J.K. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin. Cancer Res 2000, 6:278-284.
38. Yoshikawa K., Hamada J., Tada M., Kameyama T., Nakagawa K., Suzuki Y., et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed. Res 2010, 31:401-411.
39. Chan K.T., Lung M.L. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother. Pharmacol 2004, 53:519-526.
40. Dong P., Karaayvaz M., Jia N., Kaneuchi M., Hamada J., Watari H., et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32:3286-3295.
41. Bisio A., Ciribilli Y., Fronza G., Inga A., Monti P. TP53 mutants in the Tower of Babel of cancer progression. Hum. Mutat 2014, 35:689-701.
42. Goh A.M., Coffill C.R., Lane D.P. The role of mutant p53 in human cancer. J. Pathol 2011, 223:116-126.
43. Dong P., Xu Z., Jia N., Li D., Feng Y. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer 2009, 8:103.
44. Solimini N.L., Luo J., Elledge S.J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130:986-988.
45. Shen Y., Lu L., Xu J., Meng W., Qing Y., Liu Y., et al. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Cell Biol. Int 2013, 37:1114-1121.
46. Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger J.A., et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem 2006, 281:22118-22130.
47. Zannini L., Lecis D., Buscemi G., Carlessi L., Gasparini P., Fontanella E., et al. REGgamma proteasome activator is involved in the maintenance of chromosomal stability. Cell Cycle 2008, 7:504-512.
48. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?. Genes Dev 2004, 18:2046-2059.
49. Zhang Z., Zhang R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 2008, 27:852-864.
50. Saitoh M., Shirakihara T., Miyazono K. Regulation of the stability of cell surface E-cadherin by the proteasome. Biochem. Biophys. Res. Commun 2009, 381:560-565.
51. Baritaki S., Chapman A., Yeung K., Spandidos D.A., Palladino M., Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 2009, 28:3573-3585.
52. Evke E., Minbay F.Z., Temel S.G., Kahveci Z. Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J. Mol. Histol 2009, 40:13-21.
53. Slade N., Moll U.M. Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol. Biol 2003, 234:231-243.
54. Zheng T., Wang J., Zhao Y., Zhang C., Lin M., Wang X., et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat. Commun 2013, 4:2996.
55. Wiech M., Olszewski M.B., Tracz-Gaszewska Z., Wawrzynow B., Zylicz M., Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS ONE 2012, 7:e51426.
56. Sanchez N., Gallagher M., Lao N., Gallagher C., Clarke C., Doolan P., et al. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS ONE 2013, 8:e65671.
57. Xiong S., Zheng Y., Jiang P., Liu R., Liu X., Qian J., et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br. J. Cancer 2014, 110:353-362.
58. Shi Y., Luo X., Li P., Tan J., Wang X., Xiang T., et al. miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGgamma. Cancer Lett 2015, 358:27-36.